Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 247 clinical trials
Atrial Fibrillation in Patients Receiving Ibrutinib

Ibrutinib (a tyrosine kinase inhibitor targeting Bruton) is a standard of treatment in haematology. According to retrospective data, atrial fibrillation and systemic hypertension are common

tyrosine
ibrutinib
  • 0 views
  • 24 Jan, 2021
  • 1 location
LRRK2 G2385R Leucocyte and Urine Biomarker Study

effects of LRRK2 kinase inhibitor (MLi-2) on these biomarkers, using immunoblotting and mass spectrometry.

movement disorder
  • 0 views
  • 24 Jan, 2021
  • 1 location
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study

clinical outcome in patients with advanced -EGFR mutated adenocarcinoma. The investigators will compare the genetic alterations between tumors of pre and post Tyrosin Kinase Inhibitor(TKI

  • 0 views
  • 23 Jan, 2021
  • 1 location
TKI Discontinuation in CML Patients of China

The primary objective of this study is to describe the maintenance of the molecular remission after tyrosine kinase inhibitor (TKI) disconnection in chronic myeloid leukaemia (CML) patients in

remission
nilotinib
myeloid leukemia
imatinib
chronic myeloid leukemia
  • 40 views
  • 26 Jan, 2021
  • 1 location
Study on Bisphosphonates Targeting Triple-negative Breast Cancer

can be chimeric with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, which can synergistically inhibit the in vitro tumor formation of cancer (such as non-small-cell lung

  • 0 views
  • 23 Jan, 2021
  • 3 locations
The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy

, multitarget receptor tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FGFR, c-Kit, and other kinases. It functions by inhibiting tumor angiogenesis and proliferative signaling pathways. We would observe

  • 0 views
  • 16 Mar, 2021
  • 1 location
Spanish Real-World Evidence Cabozantinib

). Recently, the tyrosine kinase inhibitor (TKI) cabozantinib was approved as a first-line therapy for patients with advanced clear-cell RCC (ccRCC). Cabozantinib was initially approved for

cancer
vegf
carcinoma
ipilimumab
kinase inhibitor
  • 0 views
  • 25 Jan, 2021
  • 29 locations
Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

This pilot research trial studies the collection of blood samples in monitoring tumor specific mutations in patients with non-small cell lung cancer that has spread to other places in the body or cannot be removed by surgery. Collecting blood samples may help measure the changes in lung cancer, better learn …

tumor cells
cancer
carcinoma
biomarker analysis
measurable disease
  • 2 views
  • 22 Jan, 2021
  • 1 location
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients

Adjuvant therapy with dabrafenib plus trametinib in melanoma was approved in 2018 by the EMA (EUropean Medicines Agency). The purpose of this non-interventional study is to assess the usage of adjuvant dabrafenib and trametinib in clinical practice, where the patient population may differ from study population.

cancer
immunologic adjuvant
BRAF
immunomodulators
melanoma skin
  • 1 views
  • 11 Feb, 2021
  • 39 locations
Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment Tumor Modeling and Genomic Analysis

Objective To follow people with GISTs and collect tumor tissue so that it can be studied in the lab. Eligibility People age 6 and older who have a GIST. Design Participants will be screened with a review of their medical records and samples. Participants will enroll in 3 other NIH …

  • 0 views
  • 14 Apr, 2021
  • 1 location